Development of mRNA vaccines against respiratory syncytial virus (RSV)

Qiu, Xirui; Xu, Shisen; Yang, Lu; Luo, Zichen; Yan, Yang-Tian; Wang, Chuyue; Ji, Jianjian

doi:10.1016/j.cytogfr.2022.10.001

Cited by 39 publications

(31 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in contrast to preclinical testing in mice, in which potent CD4 + and CD8 + T cell responses were identified, 198 administration of mRNA‐1777 led to a cellular response predominated by the CD4 + T cell subset 197 . Further engineering and codon optimization has been undertaken to increase translation and improve immunogenicity resulting in an mRNA‐1345 vaccine candidate 199 . In phase 1 clinical trials, it has been tested in adults aged 18–75, demonstrating a good safety profile after single‐dose administration and leading to the generation of high titers of neutralizing antibodies for A and B type of RSV.…”

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

“…In phase 1 clinical trials, it has been tested in adults aged 18–75, demonstrating a good safety profile after single‐dose administration and leading to the generation of high titers of neutralizing antibodies for A and B type of RSV. Compared to mRNA‐1777, approximately sevenfold higher antibody titers were observed 199 . Given these promising results, mRNA‐1345 was granted by the FDA a fast‐track designation that allowed it to enter the pivotal phase 2/3 clinical trial to establish the safety and efficacy of the mRNA‐1345 vaccine in adults ≥60 years 200 .…”

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

See 1 more Smart Citation

mRNA vaccines: The future of prevention of viral infections?

Rzymski

Szuster‐Ciesielska

Dzieciątkowski

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines against COVID-19 are the first authorized biological preparations developed using this platform. During the pandemic, their administration has been proven to be a life-saving intervention. Here, we review the main advantages of using mRNA vaccines, identify further technological challenges to be met during the development of the mRNA platform, and provide an update on the clinical progress on leading mRNA vaccine candidates against different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah virus, Zika virus, human cytomegalovirus, and Epstein-Barr virus. The prospects and challenges of manufacturing mRNA vaccines in low-income countries are also discussed. The ongoing interest and research in mRNA technology are likely to overcome some existing challenges for this technology (e.g., related to storage conditions and immunogenicity of some components of lipid nanoparticles) and enhance the portfolio of vaccines against diseases for which classical formulations are already authorized. It may also open novel pathways of protection against infections and their consequences for which no safe and efficient immunization methods are currently available.

show abstract

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

Section: Clinical Progress Of Mrna Candidates Beyond Covid‐19mentioning

confidence: 99%

mRNA vaccines: The future of prevention of viral infections?

Rzymski

Szuster‐Ciesielska

Dzieciątkowski

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Several RSV mRNA vaccines encoding the RSV stabilized prefusion F protein are in clinical trials among children and adults (Table 3) [52]. The mRNA-1777 vaccine was tested in adults aged 18–49 and 60–79 years at varying i.m.…”

Section: Mrna Vaccines Against Respiratory Syncytial Virusmentioning

confidence: 99%

mRNA vaccines against respiratory viruses

Whitaker

Sahly

Healy

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review The successes of the coronavirus disease 2019 (COVID-19) mRNA vaccines have accelerated the development of mRNA vaccines against other respiratory pathogens. The aim of this review is to highlight COVID-19 mRNA vaccine advances and provide an update on the progress of mRNA vaccine development against other respiratory pathogens. Recent findings The COVID-19 mRNA vaccines demonstrated effectiveness in preventing severe COVID-19 and death. H7N9 and H10N8 avian influenza mRNA vaccines have demonstrated safety and immunogenicity in phase 1 clinical trials. Numerous seasonal influenza mRNA vaccines are in phase 1–3 clinical trials. Respiratory syncytial virus (RSV) mRNA vaccines have progressed to phase 2–3 clinical trials in adults and a phase 1 clinical trial in children. A combined human metapneumovirus and parainfluenza-3 mRNA vaccines was found to be well tolerated and immunogenic in a phase 1 trial among adults and trials are being conducted among children. Clinical trials of mRNA vaccines combining antigens from multiple respiratory viruses are underway. Summary The development of mRNA vaccines against respiratory viruses has progressed rapidly in recent years. Promising vaccine candidates are moving through the clinical development pathway to test their efficacy in preventing disease against respiratory viral pathogens.

show abstract

“…Respiratory syncytial virus (RSV) is a nonsegmented, negative strand RNA virus that has caused severe lower respiratory tract infections of high mortality rates in infants and the elderly. 1,2 In recent years, the outbreak of RSV infection in China, Europe and the United States has brought serious burden to society. [3][4][5] Currently, there are approved RSV monoclonal antibodies designed for infants and children up to 2 years of age, 6 as well as two vaccines developed for older adults.…”

Section: Introductionmentioning

confidence: 99%